dipyridamole / Generic mfg. - LARVOL DELTA

Endothelium-dependent Coronary Microvascular Dysfunction - A Diagnosis by Integrated Non-invasive Imaging. (PubMed, J Cardiovasc Echogr) - "Further assessment with dipyridamole stress echocardiography demonstrated normal coronary flow velocity reserve (CFVR) in the left anterior descending artery = 3.2, indicating preserved endothelium-independent vasodilation...In patients with ANOCA, patchy perfusion abnormalities during vasodilator stress and preserved CFVR may reflect CMD due to endothelium-dependent dysfunction. Ecostress may offer valuable diagnostic insights and support early identification and management of CMD."

Journal • Cardiovascular • CNS Disorders • Coronary Artery Disease • Depression • Pain • Psychiatry

Dipyridamole as a Perioperatively Safe Aurora Kinase A Inhibitor for Neoadjuvant Therapy in Esophageal Squamous Cell Carcinoma. (PubMed, Onco Targets Ther) - "CCK-8 assays demonstrated selective antiproliferative activity (IC50: KYSE-150 = 12.4 μM; TE-1 = 18.7 μM; EC109 = 25.3 μM at 48 h) with a selectivity index of 6.3 versus normal cells (Het-1A IC50 = 78.5 μM). Dipyridamole is an AURKA-engaging compound with an established perioperative safety profile, validated cellular target engagement, and selective anti-ESCC activity, warranting further preclinical investigation as a potential neoadjuvant adjunct."

Journal • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • AURKA

Dipyridamole-Coated 3D-Printed β-Tricalcium Phosphate Scaffolds: Spectrophotometric Characterization, Drug Release Kinetics, and In Vitro Evaluation to Guide Critical-Sized Bone Defect Repair Studies. (PubMed, J Funct Biomater) - "MTT assay demonstrated biocompatibility at all concentrations, with viability influenced by coating volume rather than drug concentration. These findings establish a foundational physicochemical framework for DIPY-loaded β-TCP scaffolds, providing the baseline data necessary to guide subsequent biological evaluation and translational efforts toward critical-sized craniofacial and orthopedic bone defect repair."

Journal • Preclinical • Orthopedics

Exploring Matrix Stiffness-Related Gene in Periodontitis: A Comprehensive Multidataset Analysis. (PubMed, Mediators Inflamm) - "COL15A1, COL4A1, CXCR4, and MMP7 were identified as biomarkers associated with MS. Bioinformatics analysis suggested that they might be involved in the progression of PD through pathways such as immune infiltration, metabolism, and inflammatory chemotaxis, providing hypothetical clues regarding the link between MS and the pathogenesis of PD; however, their specific mechanisms of action still required experimental validation."

Biomarker • Journal • Dental Disorders • Periodontitis • COL4A1 • CXCR4 • MALAT1 • MIR124-3 • MMP7

Fluvastatin Plus Dipyridamole Suppresses Canine Hemangiosarcoma Growth in Patient-Derived Xenograft Models Through Lactate Dehydrogenase-Associated Cholesterol/Lipid Metabolism. (PubMed, Vet Comp Oncol) - "In contrast, combined fluvastatin and dipyridamole treatment inhibited proliferation in vitro and tumour growth in PDX models. Collectively, these results suggest a context-dependent association between LDH and cholesterol/lipid metabolism in canine HSA cell lines and provide a rationale for further evaluation of combined cholesterol pathway inhibition."

Journal • Preclinical • Angiosarcoma • Gene Therapies • Metabolic Disorders • Oncology • Sarcoma • Solid Tumor • Transplantation • LDHA • LDHB • SREBF2

Impact of blood collection tubes on thrombin generation assay results: a comparison of citrate and CTAD. (PubMed, Sci Rep) - "Citrate-theophylline-adenosine-dipyridamole (CTAD) tubes are recommended by the manufacturer of the Ceveron® alpha TGA system due to their ability to inhibit platelet activation...In contrast, only lag time showed significant differences with the RC high reagent. In conclusion, while citrate tubes may be used for TGA, the type of blood collection tube can influence measurements under specific assay conditions and should be considered a relevant factor when comparing and interpreting TGA results."

Clinical • Journal • Pediatrics

Dipyridamole for Early-Onset Preeclampsia: A Pilot Study of Feasibility, Pharmacokinetics, and Biological Effects (clinicaltrials.gov) - P1/2 | N=15 | Not yet recruiting | Sponsor: Hadassah Medical Organization

New P1/2 trial • Cardiovascular • Gynecology • Hypertension

Highly sensitive fluorescent lateral flow immunoassay based on core-shell PS@Dip@SiO2 microspheres for SARS-CoV-2 IgG detection. (PubMed, Mikrochim Acta) - "Polystyrene (PS) microspheres were synthesized via emulsion polymerization, doped with dipyridamole (Dip), and coated with a protective silica (SiO2) shell through a sol-gel process...The detection limit for SARS‑CoV‑2 IgG was 10 ng/mL, approximately two orders of magnitude lower than that of a commercial colloidal gold‑based LFIA strip. This platform provides a rapid, sensitive, and low‑cost solution for point‑of‑care serological screening of COVID‑19."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Metal-dependent regulated cell death: Molecular architecture and translational frontiers. (PubMed, Imeta) - "To bridge the persistent knowledge gap between foundational metallobiology and clinical application, we evaluated a bidirectional therapeutic framework: exploiting synthetic lethality and metabolic gating via clinical inducers (e.g., sorafenib, elesclomol) to selectively eliminate therapy-resistant malignancies while deploying targeted pathway inhibitors and systemic agonists (e.g., dipyridamole, omaveloxolone) to limit pathological tissue degeneration in ischemic and neurodegenerative disorders. Specifically, we highlighted the integration of single-atom catalysts, stimuli-responsive nanomedicines, and biomimetic carriers engineered to spatiotemporally confine catalytic oxidative flux. Finally, we examined the systemic immunological consequences of targeted metal dysregulation, detailing how metal-induced immunogenic cell death and cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway hyperactivation reshape immunosuppressive microenvironments..."

Journal • Review • CNS Disorders • Oncology • CGAS • STING

Dipyridamole combined with immunoglobulin and aspirin in the treatment of Kawasaki disease in children: a meta-analysis. (PubMed, Front Med (Lausanne)) - "The clinical efficacy of dipyridamole combined with immunoglobulin and aspirin in treating Kawasaki disease in children is superior to that of immunoglobulin combined with aspirin, with comparable safety. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261336468, identifier CRD420261336468."

Journal • Retrospective data • Review • CRP

Heparin combined with urokinase therapy for the treatment of acute portal vein thrombosis in children. (PubMed, Pediatr Surg Int) - "The use of heparin combined with urokinase for the treatment of pediatric PVT is feasible and effective under the premise of ensuring safety. Nevertheless, further verification of its safety and effectiveness is still needed through increased sample size."

Journal • Cardiovascular • Hematological Disorders • Hypertension • Myeloproliferative Neoplasm • Oncology • Pain • Pediatrics • Portal Hypertension • Thrombosis

Hepatoprotective effect of dipyridamole against cyclophosphamide-induced hepatotoxicity in rats. (PubMed, Open Vet J) - "These findings confirm Dipyr's protective potential against Cyc-induced hepatotoxicity mainly via antioxidant and anti-inflammatory mechanisms. Dipyr may probably mitigate hepatic injuries when used as an adjuvant in patients undergoing Cyc therapy."

Journal • Preclinical • Hematological Disorders • Hepatology • Leukopenia • Liver Failure • Oncology • CAT • NFKB1

Diffusion-Controlled Drug Release from Electrospun Poly(3-hydroxybutyrate) Fibers with Beaded Architecture: An Experimental and Modeling Study. (PubMed, Int J Mol Sci) - "Poly(3-hydroxybutyrate) (PHB) was selected as the model biopolyester and dipyridamole (DPD) as the model drug...The results demonstrate that morphological parameters significantly affect diffusion and release kinetics. The controlled exploitation of bead-on-string architectures may enable the design of electrospun materials with tunable absorption of pollutant filtration, mechanical performance, and flexibility in drug release profiles, for sustainable biopolymers like PHB."

Journal

Advances in stress echocardiography: myocardial work for myocardial ischemia detection. (PubMed, J Cardiovasc Med (Hagerstown)) - "GWE analysis may be useful in improving CAD detection during Dip-SE."

Journal • Cardiovascular • Coronary Artery Disease • Myocardial Ischemia

Blunted heart rate response during dipyridamole stress SPECT is associated with cardiovascular outcomes in an all-comers cohort. (PubMed, BMC Cardiovasc Disord) - "In unselected patients referred to DS-SPECT, BHRR was associated with cardiovascular mortality. Moreover, in our population group, when combined with abnormal imaging results, BHRR significantly increases the association with DS-SPECT for cardiovascular morbidity and all-cause mortality. These findings may support future inclusion of BHRR in DS-SPECT studies."

Journal • Cardiovascular • Coronary Artery Disease • Heart Failure • Myocardial Ischemia

Antitumor effect of dipyridamole mediated by inhibiting the interaction between platelets and tumor cells. (PubMed, Discov Oncol) - "However, studies on the anti-tumor mechanisms of dipyridamole are currently limited and incomplete. In this review, we summarize the pathways through which dipyridamole disrupts platelet-tumor cell interactions and exerts antitumor effects, aiming to inform the development of novel anticancer therapies."

Journal • Review • Cardiovascular • Hematological Disorders • Oncology • Thrombosis

Abnormal active myocardial relaxation by dipyridamole stress test in suspected early-stage heart failure with preserved ejection fraction: a retrospective exploratory analysis. (PubMed, Front Cardiovasc Med) - "In suspected early-stage HFpEF, increased LV filling pressure during DipSE is associated with abnormal active myocardial relaxation. Myocardial performance is particularly impaired in patients with ST-segment depression during DipSE."

Journal • Retrospective data • Cardiovascular • CNS Disorders • Congestive Heart Failure • Depression • Heart Failure • Psychiatry

The role of ginkgo leaf extract and dipyridamole adjuvant treatment for reduction of lower limb deep vein thrombosis after proximal femoral nail antirotation surgery in elderly patients with intertrochanteric femoral fracture. (PubMed, Front Pharmacol) - "Patients were divided into a conventional group receiving rivaroxaban and a GLED group receiving rivaroxaban plus GLED. Adjuvant GLED therapy is associated with a significantly lower subacute DVT incidence after PFNA in this retrospective cohort. Further prospective studies are required to confirm a causal relationship."

Journal • Cardiovascular • Hematological Disorders • Musculoskeletal Diseases • Orthopedics • Thrombosis • Venous Thromboembolism

Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Stanford University | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2026 ➔ May 2027 | Trial primary completion date: Mar 2026 ➔ May 2027

Enrollment open • Trial completion date • Trial primary completion date • Renal Disease • Transplantation

A sulfonated diblock copolymer exhibits reversible antiplatelet activity and enables aqueous dipyridamole formulation. (PubMed, Biomater Sci) - "Ex vivo analyses performed after intravenous administration confirmed antiplatelet efficacy. These findings establish PSSNa38-b-PAaU10 as a diblock copolymer with intrinsic and reversibly controlled antiplatelet activity that also supports aqueous dipyridamole formulation, providing a basis for responsive antithrombotic systems."

Journal

Cilostazol inhibits TGF-α-induced migration of hepatocellular carcinoma cells by activating PPARγ. (PubMed, Biochem Biophys Res Commun) - "We also found that PPARγ activators, ciglitazone and pioglitazone, significantly inhibited the TGF-α-induced migration of HuH7 cells. Cilostazol and dipyridamole also inhibited the activation of AKT but not EGFR. Taken together, these results strongly suggest that cilostazol and dipyridamole inhibit TGF-α-induced HCC cell migration by suppressing the AKT pathway through PPARγ activation."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor • EGFR • PPARG

Pharmacological rescue of mitochondrial dysfunction, neurite degeneration, and premature death of ALS and AD iPSC-derived neurons. (PubMed, bioRxiv) - "Thus, DPM is a promising drug to repurpose or refine for treating neurodegenerative diseases or other diseases that would benefit by augmenting pyruvate uptake into MT. Dipyridamole, an FDA-approved drug, restores mitochondrial function and protects neurons in ALS and Alzheimer's disease."

Journal • Alzheimer's Disease • CNS Disorders • Metabolic Disorders • TARDBP

Compounding and Stability Study of Dipyridamole and Clopidogrel Pediatric Oral Suspensions. (PubMed, Int J Pharm Compd) - "Oral suspension of 10 mg.mL-1 dipyridamole is stable for 3 months at +2/+8°C before opening, 1.5 month at +2/+8°C after opening, and 15 days at 25°C/60% RH. Oral suspension of 5 mg.mL-1 clopidogrel bisulfate is stable only for 1 month at +2/+8°C before or after opening and for 7 days at 25°C/60% RH."

Journal • Pediatrics

Reply to the Letter to Editor Regarding "Impact of Coronary Microvascular Dysfunction on Left Ventricular Function After Percutaneous Coronary Intervention: Assessment With Combined Dipyridamole-Exercise Stress and Myocardial Strain/Work". (PubMed, Echocardiography) - No abstract available

Journal

Clinical Experience Using Drug-Calibrated Dilute Thrombin Time for Monitoring Bivalirudin in Pediatric Ventricular Assist Devices (ISHLT 2026) - "Antiplatelet regimens received for >50% of VAD support were aspirin (ASA) (63%), clopidogrel (8%), dipyridamole (4%), ASA/clopidogrel (8%), and ticagrelor/dipyridamole (4%). Median bivalirudin level (bleeding 2.1 vs thrombotic 2.3 mcg/mL) and aPTT (bleeding 93 vs 89 sec) within 48 hours preceding event did not differ (both p>0.05). Single (55%), dual (25%), or no (20%) antiplatelet therapies were received prior to event.Conclusion Monitoring bivalirudin using drug-calibrated bivalirudin dTT is a reasonable strategy that appears associated with excellent TTR, lower incidence of CVA (<10%) and similar bleeding rates compared to national trends."

Clinical • Cardiomyopathy • Cardiovascular • Heart Failure • Pediatrics • Thrombosis